GMC 252

Drug Profile

GMC 252

Alternative Names: GMC-252; GMC-252-L-lysine salt

Latest Information Update: 23 May 2016

Price : $50

At a glance

  • Originator Genmedica Therapeutics
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Antioxidants; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • Preclinical Dyslipidaemias

Most Recent Events

  • 15 Apr 2016 Genmedica Therapeutics plans a phase I trial for Type-2 diabetes mellitus in United Kingdom (PO) (NCT02744820)
  • 01 Apr 2016 Genmedica Therapeutics initiates a phase I trial for Type-2 diabetes mellitus in United Kingdom (PO) (NCT02744820)
  • 15 Feb 2016 Genmedica Therapeutics terminates phase-I trial in Type-2 diabetes mellitus in United Kingdom (PO) (NCT02686281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top